Oncology News | pharmaphorum

News

Gilead tags Merck for first-line triple negative breast canc...

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress

News

Merck gets EU approval for Keytruda in triple-negative breas...

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease.

News

Strike two for Novartis' lung cancer antibody canakinumab

Expectations for Novartis' canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objecti

News

BMS strikes back against Merck in EU oesophageal cancer mark...

Merck & Co's Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment in the EU earlier this year, but will now face competition from B

Gilead tags Merck for first-line triple negative breast canc...

AZ/Daiichi partner with Merck on first-line lung cancer tria...

AZ's Imfinzi is first immunotherapy to raise survival in bil...

Merck gets EU approval for Keytruda in triple-negative breas...

Strike two for Novartis' lung cancer antibody canakinumab

BMS strikes back against Merck in EU oesophageal cancer mark...

FDA orders blindness risk warning to GLP-1 agonist labels

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks